Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05PDJ
|
|||
| Drug Name |
SAGE-217b
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2; ICD-9: 296.2, 296.3] | Phase 2 | [1] | |
| Company |
Sage Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor delta (GABRD) | Target Info | Immunostimulant | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.